source
- European regulators approve Fractyl Health's first GLP-1 gene therapy clinical trialEuropean regulators have given the green light for Fractyl Health, a biotech near Boston, to begin its first human study of a GLP-1 gene therapy. The therapy aims to provide a one-time treatment t…
- Amgen initiates three late-stage trials of obesity shot MariTide, including a switch-patient studyAmgen announced the start of three new Phase 3 trials for its long-acting obesity injection, MariTide. One of the studies will enroll participants who are transitioning away from the GLP-1 therapi…